Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581333 | 0.93 | MAOA (0.60) | MAOAHRH1HTR2ACYP2A6TAAR1 | |
| SCHEMBL3593094 | 0.91 | MAOA (0.58) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL27478848 | 0.91 | MAOA (0.58) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL758587 | 0.84 | — | — | |
| SCHEMBL11803736 | 0.84 | MAOA (0.40) | MAOAHRH1HTR2ASIGMAR1ESR1 | |
| SCHEMBL28209200 | 0.82 | TAAR1 (0.52) | HTR2ACYP2A6TAAR1SMN1; SMN2LOXL2 | |
| SCHEMBL11690401 | 0.81 | SIGMAR1 (0.41) | MAOAHRH1HTR2ASIGMAR1ESR1 | |
| SCHEMBL3678682 | 0.81 | MAOA (0.62) | MAOAHRH1HTR2ACYP2A6AKT2 | |
| SCHEMBL16913071 | 0.81 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL1031911 | 0.80 | MAOA (0.34) | MAOAHRH1HTR2ATAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 859 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031596-A1 | COMPOSITION FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2024-02-15 | — | — | WO | claimed |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4188316-A1 | HAIR COSMETIC COMPOSITIONS FOR PRESERVING OR MAINTAINING THE STYLE OR SHAPE OF HAIR | L'OREAL (FR) | 2023-06-07 | — | — | EP | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2022146720-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-07-07 | — | — | WO | claimed |
| CN-114685968-A | Damp-heat-resistant polycarbonate composition and preparation method and application thereof | 金发科技股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220202674-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-06-30 | — | — | US | claimed |
| US-20220202686-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-06-30 | — | — | US | claimed |
| US-20220031589-A1 | HAIR COSMETIC COMPOSITIONS CONTAINING CATIONIC COMPOUNDS, ACRYLATE-BASED POLYMERS, FATTY COMPOUNDS, AND AMINOFUNCTIONALIZED SILICONES | L'OREAL (FR) | 2022-02-03 | — | — | US | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| CN-1281362-A | Novel combination medicine | ASTRA ZENECA BRITISH CO LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| EP-1027052-A1 | NOVEL COMBINATION | AstraZeneca UK Limited (GB) | 2000-08-16 | — | — | EP | claimed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046191-A | PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AN AMIDINE COMPOUND; FOR TREATMENT OF INFLAMMATORY DISORDERS | ASTRA PHARMACEUTICALS LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| CN-1221407-A | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMA PROD (GB) | 1999-06-30 | — | — | CN | claimed |
| WO-1999018960-A1 | NOVEL COMBINATION | ASTRAZENECA UK LIMITED (GB) | 1999-04-22 | — | — | WO | claimed |
| EP-0892784-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Astra Pharmaceuticals Limited (GB) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202686-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | CUTA, SGMS1, PHOSPHO1 | MAOA 2918/4885HRH1 663/4885HTR2A 2328/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | MAOA 1581/4885HRH1 17/4885HTR2A 937/4885 |
| US-20220031589-A1 | HAIR COSMETIC COMPOSITIONS CONTAINING CATIONIC COMPOUNDS, ACRYLATE-BASED POLYMERS, FATTY COMPOUNDS, AND AMINOFUNCTIONALIZED SILICONES | SGMS1, PHOSPHO1, SGMS2 | MAOA 2115/4885HRH1 948/4885HTR2A 1847/4885 |
| US-20220202674-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | SGMS1, MITF, SGMS2 | MAOA 3519/4885HRH1 1397/4885HTR2A 3515/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | MAOA 1431/4885HRH1 2940/4885HTR2A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.